Mirae Asset Global Investments Co., Ltd. Denali Therapeutics Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

$20 Billion
Q2 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 4,258 shares of DNLI stock, worth $121,906. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,258

Previous 71,142 94.01%

Holding current value

$121,906

Previous $1.46 Million 93.28%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	SELL	$14.96 - $23.22 $1 Million - $1.55 Million	-66,884 Reduced 94.01%	4,258 $98,000
Q1 2024 May 01, 2024	SELL	$15.83 - $23.35 $38,672 - $57,044	-2,443 Reduced 3.32%	71,142 $1.46 Million
Q4 2023 Jan 24, 2024	BUY	$16.2 - $23.18 $63,358 - $90,656	3,911 Added 5.61%	73,585 $1.58 Million
Q3 2023 Oct 26, 2023	SELL	$20.63 - $30.17 $82 - $120	-4 Reduced 0.01%	69,674 $1.44 Million
Q2 2023 Aug 10, 2023	BUY	$23.37 - $32.96 $63,099 - $88,992	2,700 Added 4.03%	69,678 $2.06 Million
Q1 2023 May 04, 2023	BUY	$21.91 - $32.67 $271,048 - $404,160	12,371 Added 22.65%	66,978 $1.54 Million
Q4 2022 Feb 09, 2023	BUY	$26.28 - $33.92 $150,032 - $193,649	5,709 Added 11.68%	54,607 $1.52 Million
Q3 2022 Nov 10, 2022	BUY	$25.97 - $38.53 $354,854 - $526,473	13,664 Added 38.78%	48,898 $1.5 Million
Q2 2022 Jul 26, 2022	BUY	$20.88 - $35.19 $735,685 - $1.24 Million	35,234 New	35,234 $1.04 Million
Q4 2021 Feb 08, 2022	SELL	$42.59 - $55.02 $298,854 - $386,075	-7,017 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$48.48 - $78.23 $56,285 - $90,825	1,161 Added 19.83%	7,017 $354,000
Q2 2021 Aug 11, 2021	BUY	$50.3 - $78.44 $294,556 - $459,344	5,856 New	5,856 $460,000

Others Institutions Holding DNLI

# of Institutions

215

Shares Held

121M

Call Options Held

127K

Put Options Held

38.3K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.84B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Denali Therapeutics Inc. Transaction History